Vivoryon ‘profoundly disappointed’ by phase 2 Alzheimer’s fail as stock crashes

The notoriously tricky indication of Alzheimer’s disease has defeated another candidate, with Vivoryon Therapeutics’ lead asset missing all endpoints in a phase 2 trial and sending the company’s stock plunging 90%.